Accessibility Menu
 

The FDA Accepted Revance Therapeutics' Application for Approval Of Its Botox Competitor

The company's frown line treatment moved closer to commercialization today.

By Todd Campbell Feb 6, 2020 at 4:09PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.